SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis

KRAS is a key oncogenic driver in lung adenocarcinoma (LUAD). Chromatin‐remodeling gene SMARCA4 is comutated with KRAS in LUAD; however, the impact of SMARCA4 mutations on clinical outcome has not been adequately established. This study sought to shed light on the clinical significance of SMARCA4 mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liang, Ahmed, Tamjeed, Petty, William J., Grant, Stefan, Ruiz, Jimmy, Lycan, Thomas W., Topaloglu, Umit, Chou, Ping‐Chieh, Miller, Lance D., Hawkins, Gregory A., Alexander‐Miller, Martha A., O’Neill, Stacey S., Powell, Bayard L., D’Agostino, Ralph B., Munden, Reginald F., Pasche, Boris, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858279/
https://www.ncbi.nlm.nih.gov/pubmed/33107184
http://dx.doi.org/10.1002/1878-0261.12831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858279/
https://www.ncbi.nlm.nih.gov/pubmed/33107184
http://dx.doi.org/10.1002/1878-0261.12831

Ejemplares similares